Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
6,772 total articles
WW International, Inc. announced its Q1 2026 financial results with total subscribers at 2.7 million and clinical subscribers increasing 46% year-over-year. The company reported $168 million in revenue, with clinical subscription revenue up 32%. WW reaffirmed its full-year 2026 revenue and adjusted EBITDA guidance and announced a fully subscribed d…
Climb Bio, a clinical-stage biotech company focused on immune-mediated diseases, reported its Q1 2026 financials, showing a net loss reduced from last year and a strong cash position bolstered by a recent $110 million private placement. The company provided updates on its two clinical-stage programs—budoprutug and CLYM116—highlighting positive Phas…
Akebia Therapeutics reported Q1 2026 financial results highlighted by a 60% increase in patients treated with Vafseo and Q1 net product revenues of $52.0 million, driven by growing adoption in dialysis-related anemia treatment. The company advanced clinical trials for rare kidney diseases and expects pivotal data for Vafseo dosing regimens by early…
Opus Genetics announced the completion of enrollment in Cohort 1 of its Phase 1/2 clinical trial evaluating OPGx-BEST1 gene therapy for Best Vitelliform Macular Dystrophy (BVMD) and Autosomal-Recessive Bestrophinopathy (ARB). Preliminary safety and early efficacy signals from the initial participant are promising, with topline 3-month data expected…
Widmer Brothers Brewing, a craft beer brand under Tilray Brands, Inc., has launched 'Stay Sunny', a full brand refresh across its Hefeweizen portfolio including new packaging, accessible pack formats, and a multi-month marketing campaign focused in the Pacific Northwest. The refresh introduces two new beers—Hefe Light and Timbers Pils—and emphasize…
Tecnoglass, Inc. (NYSE: TGLS) reported strong first quarter 2026 results with record revenue of $249 million, a 12% increase year-over-year. Despite margin pressure from higher raw material costs and tariffs, net income was $31.9 million and adjusted EBITDA remained robust at $61.5 million. The company expanded its backlog by 19% to $1.36 billion, …
Datadog announced its Q1 2026 financial results showing 32% year-over-year revenue growth to $1.006 billion, positive GAAP operating income, and robust free cash flow of $289 million. The company expanded its AI-driven observability and security platform with several new product launches including MCP Server, Bits AI Security Agent, GPU Monitoring,…
Monte Rosa Therapeutics announced first quarter 2026 financial results along with significant clinical progress across its molecular glue degrader (MGD) pipeline. Key highlights include positive interim data for MRT-8102 showing substantial CRP reductions in patients with elevated cardiovascular risk, preparation to initiate multiple Phase 2 trials…
AI Financial Corporation announced a strategic commercial agreement with SuperQ Quantum Computing Inc. to enhance the security and resilience of its digital asset platform infrastructure using post-quantum cryptography. The partnership will focus on protecting payment, trading, and settlement environments and evaluating infrastructure frameworks fo…
Rapport Therapeutics announces strong first quarter 2026 financial results and positive clinical updates, including sustained seizure reduction in Phase 2a data for RAP-219 in focal onset seizures, accelerated initiation of Phase 3 trials, and a new strategic collaboration with Tenacia Biotechnology for development and commercialization in Greater …
Foghorn Therapeutics reported Q1 2026 financials and corporate progress, highlighting on-track Phase 1 trial for FHD-909 in NSCLC patients with SMARCA4 mutations and compelling preclinical data showing durable tumor regression when combined with anti-PD-1 antibody. The company is advancing selective CBP and EP300 degrader programs targeting breast …
Korro Bio reported first quarter 2026 financial results, highlighting significant progress in their RNA editing platform, including advancement of the KRRO-121 program towards regulatory filing in late 2026 for treatment of hyperammonemia. The company also achieved over 90% in vivo RNA editing in early-stage research for alpha-1 antitrypsin deficie…
U.S. Energy Corporation reported Q1 2026 results highlighting transformative progress on its Big Sky Carbon Hub in Montana. Key achievements include a Final Investment Decision on Phase 1 processing facility, execution of a fixed-scope EPC contract, and a five-year 100% take-or-pay helium offtake agreement with an investment-grade industrial gas co…
Commerce.com, Inc. (Nasdaq: CMRC) announced its Q1 2026 financial results, showing 5% year-over-year revenue growth to $86.8 million and a GAAP net income of $3.7 million versus a loss in the prior year. The company's AI-driven commerce ecosystem platform is gaining momentum with increased Gross Merchandise Volume and expanding subscription revenue…
MBX Biosciences, a clinical-stage biopharmaceutical company focused on endocrine and metabolic disorders, appointed Mark R. Soued as Chief Commercial Officer. Soued brings extensive commercial leadership experience from companies like Alnylam Pharmaceuticals and Pfizer and will lead MBX's commercialization efforts as the company advances its pipeli…
NewAmsterdam Pharma (Nasdaq: NAMS) announced its first quarter 2026 financial results and provided updates on its late-stage clinical development program for obicetrapib, an oral CETP inhibitor targeting cardiovascular disease patients with elevated LDL cholesterol. Key upcoming milestones include expected regulatory decisions in the second half of…
Beam Therapeutics announced its Q1 2026 financial results and business updates highlighting promising clinical data from its lead programs including BEAM-302 for alpha-1 antitrypsin deficiency and risto-cel for sickle cell disease. The company expects to initiate pivotal trials and submit regulatory applications by year-end 2026, supported by a str…
Axsome Therapeutics, a U.S.-based biopharmaceutical company specializing in central nervous system disorders, announced its support for Mental Health Month 2026. The company shared resources and highlighted efforts to raise awareness for mental health conditions such as major depressive disorder. Axsome emphasized its mission to develop treatments …
Quantum BioPharma Ltd. reported a strong first quarter in 2026, more than doubling its liquidity through a combined cash, cash equivalents, and digital assets totaling $9.8 million. The company significantly reduced cash burn by 60% year-over-year, completed filing an IND application with the FDA for its multiple sclerosis drug candidate Lucid-MS, …
Ligand Pharmaceuticals reported robust first-quarter 2026 financial results driven by a 56% year-over-year increase in royalty revenues, attributed largely to key assets such as Travere’s Filspari and Merck’s Ohtuvayre and Capvaxive. The company reaffirmed its raised full-year guidance, anticipating incremental contributions from the pending XOMA R…
Vertex, Inc. delivered robust financial results for Q1 2026, with an 11.1% increase in total revenues and a 20.7% rise in cloud revenues year-over-year. The company acquired AI-first e-invoicing startup Brinta to expand in Latin America. Their newly announced Value Creation Plan aims to accelerate profitability and free cash flow through strategic …
Cullinan Therapeutics reports Q1 2026 financials showing a net loss of $49.7 million with cash runway into 2029. The company highlights the FDA acceptance of the NDA for zipalertinib in relapsed EGFR ex20ins NSCLC with a PDUFA date set for February 27, 2027. Clinical data presentations for its T cell engager pipeline in autoimmune diseases and onco…
USA Rare Earth, Inc. announced it will release its financial results for Q1 2026 on May 13, 2026, after U.S. market close, followed by a conference call to discuss the results. The company operates a fully integrated rare earth and permanent magnet supply chain across multiple countries and sectors.
Entrada Therapeutics announced positive topline data from Cohort 1 of its Phase 1/2 ELEVATE-44-201 study evaluating ENTR-601-44 for Duchenne muscular dystrophy (DMD) patients amenable to exon 44 skipping. The study demonstrated favorable safety and tolerability with no serious adverse events and showed statistically significant and clinically meani…
Gogo Inc. reported its Q1 2026 financial results showing a slight decrease in total revenue to $226.3 million, driven by a 5% decline in service revenue partly offset by a 22% increase in equipment revenue due to record ATG unit sales. Net income increased to $13.1 million and adjusted EBITDA was $53.3 million, up sequentially but down year-over-ye…
